Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer
Physician's Weekly,
1. Compared to alisertib alone, adding alisertib to fulvestrant did not increase objective tumour response rates to treatment…